Company intelligence / Profile preview

Aralez Pharmaceuticals Trading

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

Aralez Pharmaceuticals Trading DAC was a wholly-owned subsidiary of Aralez Pharmaceuticals Inc. that acquired and commercialized several cardiovascular and specialty pharmaceutical products, including Zontivity (vorapaxar) from Merck in September 2016 and Toprol-XL (metoprolol succinate) from AstraZeneca in October 2016. The entity dissolved on July 15, 2022.

Therapeutic areas: CardiovascularImmunologyRheumatologyNeurologyMetabolic DisordersDermatology
Modalities: Small molecule
Industry: Biotech

Partnerships

Merck: Acquired U.S. and Canadian rights to Zontivity in September 2016AstraZeneca: Acquired U.S. rights to Toprol-XL and authorized generic in October 2016

Beyond the preview

Go deeper on Aralez Pharmaceuticals Trading.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aralez Pharmaceuticals Trading.

Explore the full profile